KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Intangibles (2016 - 2025)

Astrazeneca has reported Intangibles over the past 11 years, most recently at $37.8 billion for Q4 2025.

  • Quarterly results put Intangibles at $37.8 billion for Q4 2025, up 1.8% from a year ago — trailing twelve months through Dec 2025 was $37.8 billion (up 1.8% YoY), and the annual figure for FY2025 was $37.8 billion, up 1.8%.
  • Intangibles for Q4 2025 was $37.8 billion at Astrazeneca, up from $37.2 billion in the prior quarter.
  • Over the last five years, Intangibles for AZN hit a ceiling of $39.3 billion in Q4 2022 and a floor of -$25.3 billion in Q4 2021.
  • Median Intangibles over the past 5 years was $37.2 billion (2024), compared with a mean of $18.4 billion.
  • Biggest five-year swings in Intangibles: crashed 220.67% in 2021 and later soared 1273.37% in 2024.
  • Astrazeneca's Intangibles stood at -$25.3 billion in 2021, then surged by 255.51% to $39.3 billion in 2022, then tumbled by 93.11% to $2.7 billion in 2023, then soared by 1273.37% to $37.2 billion in 2024, then increased by 1.8% to $37.8 billion in 2025.
  • The last three reported values for Intangibles were $37.8 billion (Q4 2025), $37.2 billion (Q4 2024), and $2.7 billion (Q4 2023) per Business Quant data.